Brain Cancer

An update on PFS and OS data from the phase 1 MAGIC-G1 study of MTX110 in recurrent glioblastoma has been released.

The FDA has granted rare pediatric disease designation to LP-184 in malignant rhabdoid tumors, rhabdomyosarcoma, and hepatoblastoma.

The phase 2 trial of the gamma-delta T-cell therapy INB-400 plus temozolomide in patients with newly diagnosed GBM has suspended enrollment.

This list features a snapshot of key August FDA oncology decisions, efforts to integrate health equity into guideline development, and more.

Seema Nagpal, MD, discusses the significance of the FDA approval of vorasidenib for adult and pediatric patients with IDH1/2-mutant glioma.

Here is your snapshot of all therapeutic options that the FDA approved in August 2024 and their clinical implications.

An NDA has been submitted to the FDA for TLX101-CDx for the characterization of progressive or recurrent glioma in adult and pediatric patients.

Opaganib has received orphan drug designation from the FDA for use in patients with neuroblastoma.

The FDA has awarded rare pediatric disease designation and orphan drug designation to INV724 for the treatment of neuroblastoma.

Rhenium obisbemeda proved feasible and safe for patients with leptomeningeal metastases in an interim analysis of the phase 1 ReSPECT-LM trial.

The FDA has approved vorasidenib for grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation.

The European Medicines Agency has approved Avzivi, a biosimilar referencing bevacizumab.

Paxalisib improved OS over SOC in patients with newly diagnosed glioblastoma and unmethylated MGMT promotor status.

The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion for Avzivi, a monoclonal antibody referencing bevacizumab.

AGuIX has been granted FDA fast track designation in malignant gliomas and glioblastoma.

Sarah ES Leary, MD, MS, details the significance of the FDA-approval of tovorafenib for patients with relapsed or refractory BRAF-positive pediatric low-grade glioma.

James Knight, MD, discusses a case study of a patient with brain metastases from prostate cancer and the importance of multidisciplinary, comprehensive care.

Hideho Okada, MD, PhD, discusses cancer immunoprevention through the lens of vaccine approaches in patients with low-grade glioma.

In case you missed it, below is your guide to the important regulatory approvals made by the FDA in April 2024.

Leland Metheny, MD, discusses how agents such as Iomab-B have potential to shift practice in the hematologic malignancy space.

Vebreltinib has received approval from China’s NMPA in pretreated IDH-mutant, PTPRZ1-MET fusion–positive astrocytoma or glioblastoma.

The FDA granted accelerated approval to tovorafenib for pediatric patients relapsed/refractory low-grade glioma with a BRAF fusion/rearrangement or a BRAF V600 mutation.

In case you missed any, below is a recap of every episode of OncLive On Air that aired in March 2024.

The database of the phase 1/2 trial of EO2401 in combination with nivolumab with or without bevacizumab in recurrent glioblastoma has locked.

The PET imaging agent TLX101-CDx has received FDA fast track designation for the characterization of progressive or recurrent glioma.

Early safety and efficacy data seen with AZD1390 in a phase 1 study indicate it's potential utility as a radiosensitizing treatment in glioblastoma.

The cancer vaccine immunotherapeutic VBI-1901 generated disease control in patients with recurrent glioblastoma.

Grant winner Tyler Miller, MD, PhD, outlines innovative plans for glioma research.

Treatment with a next-generation CAR T-cell agent displayed early efficacy in a small group of patients with glioblastoma.

A CAR T-cell therapy directed toward 2 brain tumor–associated proteins displayed preliminary activity in recurrent glioblastoma.